About Rayzon - About Rayzon - 湖南瑞生医疗科技有限公司

About Rayzon

Rayzon was established in 2019 and has operations in Changsha, Beijing, Shanghai, Hong Kong, Germany, etc. We embrace the prin ciples of patients first, professionalism and innovation. We are an international ophthalmic health technology company that incorpo rates research and development, manufacture, commercialization, and service.

Rayzon closely collaborates with healthcare providers and research institutions worldwide, striving to develop products that better meet the needs of doctors and patients, and benefit everyone in the world. Through in house research and development, investments, we have established a rich product line collaborations for optometry and ophthalmology.

Insightful
洞察探索

We believe it is patient needs that drive the development of medical products enterprises. Only with insights of patient needs can we carry out constant and successful innovation.

Self-Motivated
自主驱动

We are a medical technology enterprise integrates research and development, manufacture and commercialization. We believe the achievement of each strategic goal comes from diligent thinking and action, therefore we advocate a self-motivated culture.

People- First
以人为本

We listen to our patients, physicians, partners, with passion, and provide them with accessible solutions. We respect and care for each employee’s physical and mental health, quality of life and career development.

Focus & Enterprising
专注进取

We strive to be industry leader, dare to enter the unknown, and have the passion to consistently exceed ex-pectations. We focus on every detail of our products, every interaction with patients and doctors, and strive to challenge higher goals.

Milestones

1952

HumanOptics was founded in Germany, focusing on the R&D, manufacturing, and commercialization of intraocular lenses.

2011

Launched the world's first Artificial Iris.

2019

Rayzon Group was established, focusing on orthokeratology lenses and solutions.

Acquired HumanOptics AG, expanding into premium ophthalmic implant products.

Established the Optical R&D Laboratory.

2020

The China facility entered production, establishing large-scale manufacturing capability.

Established Precision Manufacturing and Materials R&D Laboratories.

2021

Acquired German Actiol, strengthening ophthalmic material R&D, manufacturing, and supply chain capabilities.

2023

Defocus Lens launched.

Acquired 2nd Sight, entering the ophthalmic surgical knife market.

2024

Orthokeratology Lens launched.

2025

Scleral Lens launched.

Third-Generation Surgical Knife launched.

2026

Enhanced Monofocal IOL launched.

Artificial Iris launched.

Ophthalmic Trocar launched.

2027

IOL Injector System to be launched.

EDOF lOL to be launched.

Fourth-Generation Surgical Knife to be launched.

1952

2011

2019

2020

2021

2023

2024

2025

2026

2027

Culture

董事长寄语

设计需要占位文字请客户提供设计需要占位文字，请客户提供设计需要占位文字，请客户提供设计需要占位文字请客户提供设计需要占位文字请客户提供，设计需要占位文字请客户提供设计需要占位文字请客户提供，设计需要占位文字请客户提供设计需要占位文字请客户提供设计需要占位文字，请客户提供设计需要占位文字，请客户提供设计需要占位文字。

ESG

Facing the international community, we aim to be the benchmark for'quality'and'service' in the ophthalmology industry. We extend our service scope to the pre‑diagnosis and post‑surgery stages, disseminate knowledge about ophthalmic diseases and eye care, and dispel public fears and misconceptions regarding such conditions.

Long‑term service cycle

We extend our service scope to the pre‑diagnosis and post‑surgery stages.

High‑quality service

Facing the international community, we aim to be the benchmark for quality and service in the ophthalmology industry.

Popular science on disease prevention

We disseminate knowledge about ophthalmic diseases and eye care, and dispel public fears and misconceptions regarding such conditions.

To Public

We are a trusted ophthalmic brand.
To Patients And Eyecare Professionals

We are eye health solution provider.
To Employees

We respect, care for and develop our employees.
To Government

We are an honest enterprise dedicated to helping pa-tients solve their ophthalmic problems.